<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20130521//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Oral Maxillofac Res</journal-id>
<journal-id journal-id-type="publisher-id">JORM</journal-id>
<journal-title-group>
<journal-title>Journal of Oral &amp; Maxillofacial Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2029-283X</issn>
<publisher>
<publisher-name>Stilus Optimus</publisher-name>
<publisher-loc>Kaunas, Lithuania</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">v13n4e3ht</article-id>
<article-id pub-id-type="doi">10.5037/jomr.2022.13403</article-id>

<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Potential Histopathological and Immune Biomarkers in Malignant and Non-Malignant Oral Lesions</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author" id="contrib1">
<name>
<surname>de Souza</surname>
<given-names>Vinícius Gonçalves</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" id="contrib2">
<name>
<surname>de Lourdes Carvalho</surname>
<given-names>Aparecida</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" id="contrib3" corresp="yes">
<name>
<surname>Miranda</surname>
<given-names>Carla Silva Siqueira</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" id="contrib4">
<name>
<surname>Cardoso</surname>
<given-names>Ludimila Paula Vaz</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
</contrib-group>

<aff id="aff1" rid="aff1">
<sup>1</sup>
<institution>Medicine course, Federal University of Jataí, Jataí</institution><country>Brazil.</country>
</aff>

<author-notes>
<corresp>Carla Silva Siqueira Miranda, 
<institution>Academic Unit of Health Sciences</institution>
<institution>Federal University of Jataí</institution>
<addr-line>Zipcode: 75803-615, Jataí-GO, BR 365, Km194, number 3800</addr-line>
<addr-line>Class of Teachers II, number 26, Jatobá campus - University City, Jataí, GO</addr-line>
<country>Brazil</country>
<phone>+55 64 36068234</phone>
<email>carlassiqueira@ufj.edu.br</email>
</corresp>
</author-notes>

<pub-date pub-type="collection">
<season>Oct-Dec</season>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>13</volume>
<issue>4</issue>
<elocation-id>e3</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>12</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>12</month>
<year>2022</year>
</date>
</history>
<permissions>

<copyright-statement>Copyright &#169; de Souza VG, de Lourdes Carvalho A, Miranda CSS, Cardoso LPV. Published in the JOURNAL OF ORAL &amp; MAXILLOFACIAL RESEARCH (http://www.ejomr.org), 31 December 2022.
</copyright-statement>
<copyright-year>2022</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
<license-p>
This is an open-access article, first published in the JOURNAL OF ORAL &amp; MAXILLOFACIAL RESEARCH, distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 UnportedLicense (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work and is properly cited. The copyright, license information and link to the original publication on (http://www.ejomr.org) must be included.</license-p>
</license>
</permissions>

<self-uri xlink:href="http://www.ejomr.org/JOMR/archives/2022/4/e3/v13n4e3ht.htm" xlink:type="simple"/>


<abstract>
<title>ABSTRACT</title>
<sec sec-type="objectives">
<title>Objectives</title>
<p>The presented case-control study was developed to characterize the clinical, histopathological and immunological profile of patients with traumatic injuries, benign neoplasms, potentially malignant oral disorders and malignant neoplasms of the oral cavity, in order to identify biomarkers of malignancy.</p>
</sec>
<sec sec-type="material and methods">
<title>Material and Methods</title>
<p>Clinical information was collected from dental records and several techniques were performed, including histopathological evaluation in sections stained with haematoxylin and eosin, immunohistochemistry for programmed death ligand-1 and measurement of serum levels of interferon-gamma, interleukin-6, -10 and -12. Statistical analysis was performed using IBM SPSS<sup>&#174;</sup> Statistics software.</p>
</sec>
<sec sec-type="results">
<title>Results</title>
<p>This study included 8 patients with traumatic injuries, 8 with benign neoplasms, 6 with potentially malignant oral disorders and 11 with malignant neoplasms. An association was observed between the classification of the lesion and smoking (P &lt; 0.05), the size of the lesion (P &lt; 0.05), the density of the inflammatory infiltrate (P &lt; 0.001), the degree of dysplasia (P &lt; 0.01) and programmed death ligand-1 expression (P &lt; 0.01).</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>Therefore, it is suggested that smoking, the size of the lesion, the inflammatory infiltrate and the programmed death ligand-1 expression can be considered potential biomarkers of oral malignancy.</p>
</sec>
</abstract>

<kwd-group>
<kwd>immune checkpoint inhibitors</kwd>
<kwd>mouth diseases</kwd>
<kwd>tumor biomarkers</kwd>
<kwd>tumor microenvironment</kwd>
</kwd-group>
</article-meta>
</front>

<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>The oral cavity is an anatomical site with particular physiological characteristics, being directly exposed to environmental factors, such as smoking, viral infections, food and the use of prostheses. Thus, this site is highly susceptible to a wide spectrum of injuries, including traumatic and reactive injuries, benign proliferative disorders, potentially malignant disorders and neoplasms [<xref ref-type="bibr" rid="B1">1</xref>]. </p>
<p>In Brazil, oral cancer (OC) is the 5<sup>th</sup> most common cancer in men and the 13<sup>th</sup> most frequent in women. The main risk factors of OC are smoking and alcoholism. Other risk factors including excessive sun exposure (in the cases of lip cancer), obesity, human papillomavirus infection (in the case of oropharyngeal cancer) and exposure to work-related carcinogens [<xref ref-type="bibr" rid="B2">2</xref>].</p>
<p>The diagnosis of OC comprises the clinical evaluation and the performance of complementary exams. Clinical examination followed by histopathological analysis of the tissue remains the gold standard for diagnosis and therapeutic indication [<xref ref-type="bibr" rid="B3">3</xref>]. </p>
<p>The identification of biomarkers has been the subject of several studies in the diagnostic and prognostic evaluation and in the management of different oral lesions, especially in malignant disorders. Tissue, serum and saliva samples are used in the evaluation of the genome, transcriptome, metabolome and proteome in studies of potential biomarkers [<xref ref-type="bibr" rid="B4">4</xref>].</p>
<p>Regarding OC, studies indicate that the concentration of proinflammatory cytokines, such as interleukin (IL) 1 beta, IL-6, IL-8, IL-12 and tumour necrosis factor can significantly reduce the proliferation of neoplastic cells [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. On the other hand, an inflammatory microenvironment can favour the expression of inhibitory molecules by the cells of the tumour microenvironment, such as programmed death-1 (PD-1) and its ligand (PD-L1), in an attempt to evade the immune system, leading to a worse prognosis for patients [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. </p>
<p>In this context, studies that allow a better understanding of the immune response in oral disorders and tumour progression and its association with the tissue microenvironment are essential in the early diagnosis, prognosis and treatment approach, mainly in the indication of immunotherapy. Therefore, it is a case-control study that was developed to characterize the clinical, histopathological and immunological profile of patients with traumatic injuries, benign neoplasms, potentially malignant oral disorders and malignant neoplasms of the oral cavity, in order to identify biomarkers of malignancy. </p>
</sec>

<sec sec-type="materials|methods">
<title>MATERIAL AND METHODS</title>
<p><bold>Selection of patients</bold></p>
<p>This study included patients who visited a public dental service in Jataí, Brazil between July 2017 and February 2020 for traumatic injuries (TI), benign tumors (BN), potentially malignant oral disorders (PMOD), or malignant tumors (MN). Nine control subjects, matched for sex and age, seen at the same health service, were included. These individuals were submitted to oral cavity analysis for oral hygiene and to exclude any clinically identifiable lesions. In this study, only mucosal lesions were included. Patients that presented allergies, autoimmune diseases or systemic inflammatory conditions and/or that use corticosteroids and anti-inflammatory drugs were excluded. This study was approved by the Research Ethics Committee of Federal University of Goiás (#3,443,761). </p>
<p><bold>Clinical evaluation</bold></p>
<p>The patients were submitted to the collection of clinical data in standardized dental record. For this study, information was collected on age, sex, ethnicity, harmful life habits (smoking, drinking, excessive sun exposure and others) and clinical data of the lesion (anatomical site, size, shape and colour). </p>
<p><bold>Sample collection</bold></p>
<p>Patients with oral lesions were submitted to incisional or excisional biopsy, depending on the clinical situation. The material was stored in 10% formaldehyde. In addition, samples of venous whole blood were collected from all patients and controls. The samples were processed and stored at -20 ºC. </p>
<p><bold>Histopathological analysis</bold></p>
<p>Tissue samples were embedded in paraffin and sectioned in a semiautomatic microtome (RM2235 - Leica Microsystems; Wetzlar, Germany) in consecutive cuts of 4 μm thick. The materials were submitted to histological processing and stained with haematoxylin and eosin, according to protocol described in the literature [<xref ref-type="bibr" rid="B9">9</xref>]. </p>
<p>For histological gradation, PMOD were classified according to the degree of dysplasia (mild, moderate and severe) [<xref ref-type="bibr" rid="B10">10</xref>] and MN were classified according to differentiation (well, moderately and poorly) [<xref ref-type="bibr" rid="B11">11</xref>]. For all lesions, the inflammatory infiltrate was classified in the cross system (+) as: 3+ (frequent and very intense), 2+ (frequent and intense), 1+ (occasional and attenuated), ± (rare and weak) and 0 (absent) [<xref ref-type="bibr" rid="B12">12</xref>]. In MN, analysis of tumour infiltrating lymphocytes (TILs) was also included, according to the protocol adapted by our research group, which are classified in 0 to 10%, 11 to 40% and 41 to 90% [<xref ref-type="bibr" rid="B13">13</xref>]. The analyses were performed by two independent pathologists, including a medical and an oral pathologist. </p>
<p><bold>Immunohistochemical analysis</bold></p>
<p>Two 4 μm sections, serialized from the material obtained for haematoxylin and eosin staining, were assembled in the analysis signalled by the marking of the PD-L1 molecule. Anti-PD-L1 antibody (clone CAL10, 1 : 400 titulation - Biocare Medical, LLC; Pacheco, California, USA) and the Starr Trek Universal HRP Detection System Kit (Biocare Medical, LLC; Pacheco, California, USA) were used. A sample of human tonsil tissue was used as positive control. Two slides from each case were used, the negative control and the case itself. </p>
<p>The material was deparaffinized in xylol and hydrated in baths of decreasing alcohol. The formolic pigment was removed with 24% ammonium hydroxide. The protocol was completed according to internal and manufacturer recommendations, including antigenic recovery in an autoclave cycle, endogenous peroxidase block with 3% hydrogen peroxide, endogenous protein block, overnight incubation with primary antibody, incubation with secondary antibody labelled with horseradish streptavidin (HRP) and stained with 3,3’-diaminobenzidine (DAB). The slides were counterstained with Harris’ haematoxylin.</p>
<p>The determination of the frequency of PD-L1+ cells and the staining profile (membrane or cytoplasm) considered positive staining for greater than or equal (≥) to 50% in tumour cells or ≥ 1% for combined staining in tumour cells and immune cells [<xref ref-type="bibr" rid="B14">14</xref>]. Cases that showed expression only in immune cells were also evaluated. PD-L1 expression was also stratified as 1%, 1 to 5%, 5 to 20% and &gt; 20%, according to the previous determination of our study group [<xref ref-type="bibr" rid="B13">13</xref>]. </p>
<p><bold>Serum cytokine determination</bold></p>
<p>The enzyme-linked immunosorbent assay (ELISA) reaction was performed using a sandwich antigen principle, according to manufacturer’s specifications, including sensitization of the plate with capture antibody, elimination of the background, determination of the standard curve, incubation of the sample, addition of detection antibody, streptavidin-HRP complex and chromogen and reading of the optical density in a spectrophotometer at 450 nm (Celer/Polaris<sup>&#174;</sup> - Celer Biotechnology S/A; Belo Horizonte, Minas Gerais, Brazil). ELISA kits were used to detect serum IL-6, IL-10, IL-12 and interferon gamma (IFN-γ) cytokines (Uncoated ELISA - InvitrogenTM; Waltham, Massachusetts, USA). </p>

<p><bold>Statistical analysis</bold></p>
<p>Statistical analysis was performed using IBM SPSS<sup>&#174;</sup> Statistics software version 26.0.0.0 (IBM Corp.; Armonk, New York, USA). Association tests were used, including the Chi-square (χ<sup>2</sup>) test and the Kruskall Wallis test. Spearman’s correlation (ρ) was also done. The numeric correlation values were categorized as very weak (ρ = 0 to 0.19), weak (ρ = 0.2 to 0.39), moderate (ρ = 0.4 to 0.69), strong (ρ = 0.7 to 0.89) and very strong (ρ = 0.9 to 1) [<xref ref-type="bibr" rid="B15">15</xref>]. The data were presented as mean and standard deviation (M [SD]). The level of significance adopted for all analyses was P &lt; 0.05. </p>
</sec>

<sec sec-type="results">
<title>RESULTS</title>
<p>This study included 8 patients with BN, 6 with PMOD, 11 with MN, 8 with TI and 9 patients without injury. Epidemiological and clinical variables are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. </p>

<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>
Epidemiological and clinical parameters of cases (n = 42)
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th  rowspan="3">Variables
</th>
<th>Without injury<break />
(n = 9)
</th>
<th>Traumatic injury<break />
(n = 8)
</th>
<th>Benign neoplasm<break />
(n = 8)
</th>
<th>Potential malignant<break />
oral disease<break />
(n = 6)
</th>
<th>Malignant neoplasm<break />
(n = 11)
</th>
<th  rowspan="3">P-value
</th>
</tr>
<tr>
  <th><hr/></th>
  <th><hr/></th>
  <th><hr/></th>
  <th><hr/></th>
  <th><hr/></th>
</tr>
<tr>
<th>N (%)
</th>
<th>N (%)
						  </th>
<th>N (%)
						  </th>
<th>N (%)
						  </th>
<th>N (%)
</th>
</tr>
</thead>
<tbody>
<tr>
<td  colspan="7" align="left">              <bold>Gender
						    </bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Male
</td>
<td align="center">6 (66.7)
</td>
<td align="center">5 (62.5)
</td>
<td align="center">3 (37.5)
</td>
<td align="center">3 (50)
</td>
<td align="center">9 (81.8)
</td>
<td  rowspan="3" align="center">0.365<sup>b</sup>
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Female
</td>
<td align="center">3 (33.3)
</td>
<td align="center">3 (37.5)
</td>
<td align="center">5 (62.5)
</td>
<td align="center">3 (50)
</td>
<td align="center">2 (18.2)
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Age (years old), mean (SD)
</td>
<td align="center">55.1 (SD 1.1)
</td>
<td align="center">50.5 (SD 2.3)
</td>
<td align="center">53.1 (SD 8.4)
</td>
<td align="center">57.8 (SD 3.2)
</td>
<td align="center">64.4 (SD 1.2)
</td>
<td align="center">0.433<sup>c</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td  colspan="7">
			                <bold>Ethnicity</bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">White
</td>
<td align="center">6 (66.7)
</td>
<td align="center">2 (25)
</td>
<td align="center">2 (25)
</td>
<td align="center">5 (83.3)
</td>
<td align="center">6 (54.5)
</td>
<td  rowspan="3" align="center">0.198<sup>b</sup>
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Black
</td>
<td align="center">3 (33.3)
</td>
<td align="center">6 (75)
</td>
<td align="center">6 (75)
</td>
<td align="center">1 (16.7)
</td>
<td align="center">5 (45.5)
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td  colspan="7">              <bold>Harmful habits
						    </bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Smoker/ex-smoker
</td>
<td align="center">2 (22.2)
</td>
<td align="center">4 (50)
</td>
<td align="center">2 (25)
</td>
<td align="center">2 (33.3)
</td>
<td align="center">9 (81.8)
</td>
<td align="center">0.022<sup>a</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Alcohol user/ex-alcoholic
</td>
<td align="center">1 (11.1)
</td>
<td align="center">3 (37.5)
</td>
<td align="center">3 (37.5)
</td>
<td align="center">1 (16.7)
</td>
<td align="center">4 (36.4)
</td>
<td align="center">0.097<sup>b</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Sun exposure
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">2 (33.3)
</td>
<td align="center">3 (27.3)
</td>
<td align="center">0.316<sup>b</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Sedentary lifestyle
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (12.5)
</td>
<td align="center">2 (25)
</td>
<td align="center">0 (0)
</td>
<td align="center">3 (27.3)
</td>
<td align="center">0.369<sup>b</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Illicit drug use
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (16.7)
</td>
<td align="center">1 (9.1)
</td>
<td align="center">0.41<sup>b</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td  colspan="7">              <bold>Lesion site
						    </bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Tongue
</td>
<td align="center">NA
</td>
<td align="center">2 (25)
</td>
<td align="center">2 (25)
</td>
<td align="center">0 (0)
</td>
<td align="center">4 (36.4)
</td>
<td  rowspan="13" align="center">0.23<sup>b</sup>
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Lower lip
</td>
<td align="center">NA
</td>
<td align="center">1 (12.5)
</td>
<td align="center">3 (37.5)
</td>
<td align="center">3 (50)
</td>
<td align="center">2 (18.2)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Throughout the oral mucosa
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (16.7)
</td>
<td align="center">0 (0)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Palate
</td>
<td align="center">NA
</td>
<td align="center">1 (12.5)
</td>
<td align="center">1 (12.5)
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (9.1)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Gingival mucosa
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (12.5)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Alveolar ridge
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (12.5)
</td>
<td align="center">2 (33.3)
</td>
<td align="center">2 (18.2)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Buccal mucosa
</td>
<td align="center">NA
</td>
<td align="center">4 (50)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">2 (18.2)
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td  colspan="7">              <bold>Size of the lesion
						    </bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">&lt; 2 cm
</td>
<td align="center">NA
</td>
<td align="center">7 (87.5)
</td>
<td align="center">7 (87.5)
</td>
<td align="center">4 (66.7)
</td>
<td align="center">2 (18.2)
</td>
<td  rowspan="3" align="center">0.032<sup>a</sup>
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">≥ 2 cm
</td>
<td align="center">NA
</td>
<td align="center">1 (12.5)
</td>
<td align="center">1 (12.5)
</td>
<td align="center">2 (33.3)
</td>
<td align="center">9 (81.8)
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<sup>a</sup>Statistically significant at level P &lt; 0.05 (Chi-square test).
</p>
<p>
<sup>b</sup>No statistically significant at level P &lt; 0.05 (Chi-square test).
</p>
<p>
<sup>c</sup>No statistically significant at level P &lt; 0.05 (Kruskall Wallis test).
</p>
<p>
N = number; NA = not applied; SD = standard deviation.
</p>
</fn>
</table-wrap-foot>
</table-wrap>

<p>Gender, age and ethnicity did not present significant difference between the groups. A significant association were found between smoking and injury classification (χ<sup>2</sup> = 14.491; P &lt; 0.05), being majority of individuals with malignant neoplasms smokers or ex-smokers (n = 9; 81.8%). Alcohol use, sun exposure, sedentary lifestyle and illicit drug use were not associated with injury classification. </p>
<p>Concerning the lesion site, no significant association was found. On the other hand, the size lesion was significant associated with injury classification (χ<sup>2</sup> = 8.774; P &lt; 0.05), being the size ≥ 2 cm present mainly in MN. </p>
<p>The diagnosis of BN included cases of papilloma (n = 3; 37.5%), haemangioma (n = 3; 37.5%), nevus (n = 2; 25%). PMOD patients presented lesions compatible with actinic cheilitis (n = 3; 50%), leukoplakia (hyperkeratosis and acanthosis with areas of dysplasia; n = 2; 33.3%) and scleroatrophic lichen planus (n = 1; 16.7%). Most MN were compatible with oral squamous cell carcinoma (OSCC) (n = 9; 81.8%), but two cases were not conclusive as to the histological subtype, being diagnosed as malignant epithelial neoplasm (n = 2; 18.2%). Finally, patients with TI presented a predominance of fibroma (n = 7; 87.5%) and one of the patients (n = 1; 12.5%) presented epithelial proliferative changes without dysplasia. </p>
<p><xref ref-type="table" rid="T2">Table 2</xref> summarizes the histopathological and immunological data. The inflammatory infiltrate was rare (n = 4; 50%) in BN, mild in PMOD (n = 5; 83.3%) and in TI (n = 8; 100%) and intense in MN (n = 5; 45.5%), with a significant association between the degree of inflammatory infiltrate and the classification of the lesion (χ<sup>2</sup> = 32.79; P = 0.001). The evaluation of TILs revealed a majority of cases of NM with an infiltration between 11 and 40% (n = 7; 63.6%), followed by 0 to 10% (n = 3; 27.3%) and 41 to 90% (n = 1; 9.1%). </p>

<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>
Histopathological and immunological parameters of cases (n = 42)
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th  rowspan="3">Variables
</th>
<th>Without injury<break />
(n = 9)
</th>
<th>Traumatic injury<break />
(n = 8)
</th>
<th>Benign neoplasm<break />
(n = 8)
</th>
<th>Potential malignant<break />
oral disease<break />
(n = 6)
</th>
<th>Malignant neoplasm<break />
(n = 11)
</th>
<th  rowspan="3">P-value
</th>
</tr>
<tr>
  <th><hr/></th>
  <th><hr/></th>
  <th><hr/></th>
  <th><hr/></th>
  <th><hr/></th>
</tr>
<tr>
<th>N (%)
</th>
<th>N (%)
	  </th>
<th>N (%)
	  </th>
<th>N (%)
	  </th>
<th>N (%)
</th>
</tr>
</thead>
<tbody>
<tr>
<td  colspan="7" align="left">              <bold>Inflammatory infiltrate
						    </bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Absent
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (12.5)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td  rowspan="9" align="center">0.001<sup>a</sup>
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Rare
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">4 (50)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Mild
</td>
<td align="center">NA
</td>
<td align="center">8 (100)
</td>
<td align="center">3 (37.5)
</td>
<td align="center">5 (83.3)
</td>
<td align="center">4 (36.4)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Moderate
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (16.7)
</td>
<td align="center">2 (18.2)
</td>
</tr>
<tr>
  <td colspan="6" align="left"></td>
  </tr>
<tr>
<td align="left">Intense
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">5 (45.5)
</td>
</tr>
<tr>
  <td colspan="7"><hr/></td>
</tr>
<tr align="left">
<td  colspan="7">
			                <bold>Dysplasia</bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">Absent
</td>
<td align="center">NA
</td>
<td align="center">8 (100)
</td>
<td align="center">8 (100)
</td>
<td align="center">0 (0)
</td>
<td align="center">NA
</td>
<td  rowspan="5" align="center">0.001<sup>a</sup>
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Mild
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">4 (66.7)
</td>
<td align="center">NA
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">Moderate
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">2 (33.3)
</td>
<td align="center">NA
</td>
</tr>
<tr>
  <td colspan="7"><hr/></td>
</tr>
<tr align="left">
<td  colspan="7">              <bold>PD-L1 expression
						    </bold></td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">0%
</td>
<td align="center">NA
</td>
<td align="center">8 (100)
</td>
<td align="center">8 (100)
</td>
<td align="center">5 (83.3)
</td>
<td align="center">4 (36.4)
</td>
<td  rowspan="7" align="center">0.009<sup>a</sup>
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">1%
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">1 (16.7)
</td>
<td align="center">0 (0)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">1 to 5%
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">4 (36.4)
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td align="left">5 to 20%
</td>
<td align="center">NA
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">0 (0)
</td>
<td align="center">3 (27.3)
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">IL-6 levels (pg/mL), mean (SD)
</td>
<td align="center">0.5 (SD 0.1)
</td>
<td align="center">0.5 (SD 1.2)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">2.2 (SD 3.9)
</td>
<td align="center">0.411<sup>b</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">IL-10 levels (pg/mL), mean (SD)
</td>
<td align="center">3.7 (SD 11.2)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">1.5 (SD 3.6)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">0.4 (SD 1.1)
</td>
<td align="center">0.44<sup>b</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">IL-12 levels (pg/mL), mean (SD)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">0.3 (SD 0.6)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">0.305<sup>b</sup>
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td align="left">IFN-γ levels (pg/mL), mean (SD)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">1.1 (SD 3)
</td>
<td align="center">0 (SD 0)
</td>
<td align="center">15.4 (SD 40.6)
</td>
<td align="center">0.496<sup>b</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<sup>a</sup>Statistically significant at level P &lt; 0.05 (Chi-square test).
</p>
<p>
<sup>b</sup>No statistically significant at level P &lt; 0.05 (Kruskall Wallis test).
</p>
<p>
N = number; NA = not applied; SD = standard deviation; PD-L1 = programmed death ligand-1; IL = interleukin; IFN-γ = interferon gamma.
</p>
</fn>
</table-wrap-foot>
</table-wrap>

<p>Regarding structural changes, there was a predominance of cases without dysplasia in BN (n = 8; 100%) and TI (n = 8; 100%) and mild dysplasia in PMOD (n = 4; 66.7%), with a significant association between the degree of dysplasia and the classification of the lesion (χ<sup>2</sup> = 23.867; P = 0.002). As for MN, there was a predominance of moderately differentiated tumours (n = 5; 45.5%), followed by well differentiated tumours (n = 3; 27.3%) and poor differentiated tumour (n = 3; 27.3%).</p>
<p>PD-L1 expression was observed in 1 case of PMOD (n = 1, 16.7%) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), with a gradation of 1%, and in 7 cases of MN (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), with the majority of cases ranging from 1 to 5% (n = 4, 36.4%). A significant association was found between the expression of PD-L1 and the classification of the lesion (χ<sup>2</sup> = 22.04; P = 0.009). PD-L1 expression was also positively correlated with the degree of inflammatory infiltrate (ρ = 0.63; P &lt; 0.001) and with the density of TILs (ρ = 0.588; P &lt; 0.05). However, PD-L1 expression was not correlated with dysplasia, gradation and serum cytokine levels (P &gt; 0.05). </p>

  <fig id="fig1">
  <label>Figure 1</label>
  <caption>
  <p>
Immunohistochemistry for programmed death ligand-1 (PD-L1). Scale bar: 50μm. Original magnification x200.
  </p><p>
A = expression of PD-L1 in a case of actinic cheilitis. The expression is located mainly in the basal epithelial cells and in some inflammatory cells.
  </p><p>
B = greater expression of PD-L1 in a case of oral squamous cell carcinoma. Several tumour cells and some immune cells showed the expression of the molecule.
  </p>
  </caption>
  <graphic xlink:href="jomr-13-e3-g001.tiff"/>
  </fig>

<p>The differences between cytokine serum levels were not statistically significant. However, we highlight that the serum IL-10 levels increased in the control group compared to other groups, while IFN- γ was higher in MN when compared to other groups. Serum levels of IFN-γ were correlated only with the levels of IL-6 (ρ = 0.462; P &lt; 0.05) and IL-12 (ρ = 0.676; P &lt; 0.001). The serum levels of cytokines were not correlated with epidemiological and clinical parameters (P &gt; 0.05).</p>
</sec>

<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>The literature suggests that male individuals have a greater predilection for the development of malignant neoplasms, as observed in our study, especially due to the higher prevalence of smoking and alcohol consumption in this population [<xref ref-type="bibr" rid="B16">16</xref>]. In addition, it is suggested that women are at increased risk of developing traumatic and/or vascular and connective tissue injuries, possibly due to hormonal conditions [<xref ref-type="bibr" rid="B1">1</xref>]. This observation applies to our study in the context of benign neoplasms, but not in the context of traumatic injuries. Besides that, the prevalence of oral lesions is higher in individuals over 45 years old, as observed in this study, mainly due to the accumulation of harmful habits and iatrogenic factors in the oral cavity [<xref ref-type="bibr" rid="B1">1</xref>]. There is a progressive increase in the incidence of oral carcinoma in older individuals, as observed in our study, reaching a plateau around 70 to 79 years [<xref ref-type="bibr" rid="B16">16</xref>].</p>
<p>Smoking and alcohol consumption are important risk factors in the progression of oral lesions, acting in isolation or synergistically. Both conditions alter the metabolism of the cells of the oral mucosa and facilitate and/or promote genetic mutations [<xref ref-type="bibr" rid="B16">16</xref>]. Thus, this study reinforces the importance of these risk factors in the context of oral lesions, especially in PMOD and MN. </p>
<p>The labial mucosa and the buccal vestibule are more exposed to deleterious factors such as chronic irritation, mechanical and thermal injuries and bites [<xref ref-type="bibr" rid="B1">1</xref>]. That characteristic justifies the susceptibility of these regions to oral lesions, as observed in this study, which showed a predominance of BN, TI and PMOD in these regions. In the case of oral carcinoma, tongue lesions predominate, especially in the lateral border [<xref ref-type="bibr" rid="B17">17</xref>], as observed in this study.</p>
<p>Oral MN can appear as spots, plaques, tumours or ulcers, erythematous, leukoplastic, necrotic or mixed in colour, with a size greater than two centimetres [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Benign lesions, on the other hand, usually manifest as pedunculated or sessile erythematous mass with less than one centimetre in size [<xref ref-type="bibr" rid="B1">1</xref>]. These findings agree with what was observed in this study, being suggested that size may assist in the differential diagnosis, considering the greater frequency of MN greater than two centimetres. </p>
<p>The inflammatory infiltrate is an essential component of the tumour microenvironment. Recent studies demonstrate that the infiltrate can contribute to tumour progression, stimulation tissue invasion, or in its control, through the recognition and destruction of tumour cells. In terms of immunofluorescence assay, there was a general increase in the inflammatory infiltrate of patients with PMOD, compared to individuals with non-neoplastic lesions, and patients with OSCC presented a greater infiltration in related to the other two groups [<xref ref-type="bibr" rid="B18">18</xref>], corroborating the histopathological findings in this study. </p>
<p>The assessment of the degree of dysplasia remains one of the most important parameters in the prognostic assessment of patients. It is expected that patients with PMOD have degrees of dysplasia than patients with BN and TI, considering the higher frequency of exposure to carcinogens that promote genetic and morphological changes [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B19">19</xref>].</p>
<p>The PD-1/PD-L1 axis is an important immune system inhibitor pathway with already known repercussions on tumour progression and metastasis [<xref ref-type="bibr" rid="B7">7</xref>]. The infiltrate of TILs, the production of cytokines and the expression of PD-L1 have already been proposed as potential biomarkers for the use of immunotherapy [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p>
<p>The expression of PD-L1 in dysplastic oral lesions has been described in recent studies. An increase in the expression of PD-L1 was observed in dysplastic basal cells and inflammatory cells in lesions that evolve to malignancy, indicating that the increase in the expression of PD-L1 precedes tissue invasion and malignant transformation [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. This study reinforces these results, with a greater expression of PD-L1 in MN compared to PMOD, BN and TI. </p>
<p>The inflammatory infiltrate directly correlates with the expression of PD-L1 due to the ability of IFN-γ to induce the expression of the molecule. Thus, this study corroborates some works in the literature that indicated greater expression of PD-L1 in tumours with greater inflammatory infiltrate, especially in the case of TILs [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. However, in this study the expression of PD-L1 did not correlate with the serum levels of IFN-γ, indicating a possible divergence between the tissue and serum microenvironment. </p>
<p>IL-6 has different biological activities, including increasing the release of transcription factors such as AP-2, capable of activating the Ras/MAPK pathway, in addition to inactivating the p53 gene, suppressing apoptosis and promoting progressive cell growth. There are already reports in the literature that higher levels of salivary IL-6 are detected in patients with oral cancer compared to patients with leukoplakia, chronic inflammatory diseases and healthy individuals, but there was no significant difference in serum IL-6 [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. In this sense, it is also important to note that in this study the levels of cytokines were not correlated with comorbidities and harmful habits, which could acts as confounded factors in the analysis. </p>
<p>The immune response can be synthesized in two large groups: proinflammatory response, associated with Th1 lymphocytes and cytokines such as IFN-γ and IL-12, and anti-inflammatory response, associated with Th2 lymphocytes and cytokines such as IL-10. The studies presented in the literature reveal a heterogeneity regarding the levels of cytokines in patients with head and neck cancer, reinforcing the very heterogeneity of these tumours [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. In this study, a pattern of greater expression of proinflammatory cytokines, especially IFN-γ was observed in patients with malignant neoplasms, while IL-10 was more expressed in health patients. </p>
<p>In addition, a correlation was observed between the levels of IFN-γ, IL-12 and IL-6. These results suggest that the sample of this study included patients with inflammatory microenvironments, mainly in malignant lesions, despite the lack of statistical significance between the histopathological evaluation and cytokine measurement. Thus, it is expected that these patients are potential candidates for immunotherapeutic treatments and will evolve with a good prognosis. </p>
<p>It is also important to note that the detection of cytokines in unstimulated serum is hardier than in stimulated samples [<xref ref-type="bibr" rid="B26">26</xref>], which could justify the elevate number of samples with no detection of cytokines in this study. So, it is possible that in some cases, such as OPMD diseases, the lack of detection indicate a false negative result. </p>
</sec>

<sec sec-type="conclusions">
<title>CONCLUSIONS</title>
<p>This study presented the limitations of the study sample, the heterogeneity of lesions and the lack of detection of cytokines in several unstimulated samples. Despite of that, this study endorses the importance of clinical, histopathological and immunological evaluation in the early diagnosis and prognosis of patients with oral lesions, besides the possibility of individualization in the treatment of the patient. It is suggested the importance of potential biomarkers in the identification of malignant lesions, especially smoking, lesions larger than &gt; 2 centimetres, more intense inflammatory infiltrate and greater expression of programmed death ligand-1. In addition, the identification of inflammatory microenvironments associated with greater expression of programmed death ligand-1 may be relevant in the context of the indication and prognosis of immunotherapeutic treatment. It is also highlighted that new studies should be developed in order to minimize the confounded factors in microenvironment analysis of oral lesions and to identify histopathological and immune biomarkers of prognosis. </p>
</sec>
</body>

<back>
<ack>
<sec sec-type="acknowledgments and disclosure statements">
<title>ACKNOWLEDGMENTS AND DISCLOSURE STATEMENTS</title>
<p>We are grateful to the team at the Stomatological Diagnostic Clinic of the Southwest of Goiás (ADESGO) and the Histopathological Diagnosis Center (CEDHIPA) for authorizing the use of samples and clinical data of patients treated at their service.</p>
</sec>
</ack>

<ref-list>
<title>REFERENCES</title>
    <ref id="B1"><label>1</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Błochowiak</surname>
<given-names>K</given-names>
</name><name>
<surname>Farynowska</surname>
<given-names>J</given-names>
</name><name>
<surname>Sokalski</surname>
<given-names>J</given-names>
</name><name>
<surname>Wyganowska-Świątkowska</surname>
<given-names>M</given-names>
</name><name>
<surname>Witmanowski</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>
Benign tumours and tumour-like lesions in the oral cavity: a retrospective analysis. Postepy Dermatol Alergol. 2019 Dec;36(6):744-751.</source>
<pub-id pub-id-type="pmid">31998005</pub-id>
<pub-id pub-id-type="pmcid">PMC 6986298</pub-id>
<pub-id pub-id-type="doi">10.5114/ada.2018.78805</pub-id>
</element-citation>
    </ref>
    <ref id="B2"><label>2</label>
      <element-citation>
<source>
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: Incidência de Câncer no Brasil. Rio de Janeiro; 2019. p.120. URL: </source>
<comment><ext-link ext-link-type="uri" xlink:href="https://www.inca.gov.br">https://www.inca.gov.br</ext-link></comment>
</element-citation>
    </ref>
    <ref id="B3"><label>3</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Wolff</surname>
<given-names>KD</given-names>
</name><name>
<surname>Follmann</surname>
<given-names>M</given-names>
</name><name>
<surname>Nast</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>
The diagnosis and treatment of oral cavity cancer. Dtsch Arztebl Int. 2012 Nov; 109(48):829-35.</source>
<pub-id pub-id-type="pmid">23248713</pub-id>
<pub-id pub-id-type="pmcid">PMC 3523261</pub-id>
<pub-id pub-id-type="doi">10.3238/arztebl.2012.0829</pub-id>
</element-citation>
    </ref>
    <ref id="B4"><label>4</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Zhong</surname>
<given-names>L</given-names>
</name><name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name><name>
<surname>Wang</surname>
<given-names>K</given-names>
</name><name>
<surname>He</surname>
<given-names>Z</given-names>
</name><name>
<surname>Gong</surname>
<given-names>Z</given-names>
</name><name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</name><name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name><name>
<surname>Gao</surname>
<given-names>X</given-names>
</name><name>
<surname>Li</surname>
<given-names>F</given-names>
</name><name>
<surname>Wu</surname>
<given-names>H</given-names>
</name><name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name><name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
</person-group>
<source>
Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer. 2018 Sep 21;18(1):911.</source>
<pub-id pub-id-type="pmid">30241505</pub-id>
<pub-id pub-id-type="pmcid">PMC 6151070</pub-id>
<pub-id pub-id-type="doi">10.1186/s12885-018-4806-7</pub-id>
</element-citation>
    </ref>
    <ref id="B5"><label>5</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Brailo</surname>
<given-names>V</given-names>
</name><name>
<surname>Vucicevic-Boras</surname>
<given-names>V</given-names>
</name><name>
<surname>Lukac</surname>
<given-names>J</given-names>
</name><name>
<surname>Biocina-Lukenda</surname>
<given-names>D</given-names>
</name><name>
<surname>Zilic-Alajbeg</surname>
<given-names>I</given-names>
</name><name>
<surname>Milenovic</surname>
<given-names>A</given-names>
</name><name>
<surname>Balija</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>
Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal. 2012 Jan 1;17(1):e10-5.</source>
<pub-id pub-id-type="pmid">21743397</pub-id>
<pub-id pub-id-type="pmcid">PMC 3448188</pub-id>
<pub-id pub-id-type="doi">10.4317/medoral.17323</pub-id>
</element-citation>
    </ref>
    <ref id="B6"><label>6</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Lisa Cheng</surname>
<given-names>YS</given-names>
</name><name>
<surname>Jordan</surname>
<given-names>L</given-names>
</name><name>
<surname>Gorugantula</surname>
<given-names>LM</given-names>
</name><name>
<surname>Schneiderman</surname>
<given-names>E</given-names>
</name><name>
<surname>Chen</surname>
<given-names>HS</given-names>
</name><name>
<surname>Rees</surname>
<given-names>T</given-names>
</name>
</person-group>
<source>
Salivary interleukin-6 and -8 in patients with oral cancer and patients with chronic oral inflammatory diseases. J Periodontol. 2014 Jul;85(7):956-65.</source>
<pub-id pub-id-type="pmid">24147842</pub-id>
<pub-id pub-id-type="doi">10.1902/jop.2013.130320</pub-id>
</element-citation>
    </ref>
    <ref id="B7"><label>7</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Maruse</surname>
<given-names>Y</given-names>
</name><name>
<surname>Kawano</surname>
<given-names>S</given-names>
</name><name>
<surname>Jinno</surname>
<given-names>T</given-names>
</name><name>
<surname>Matsubara</surname>
<given-names>R</given-names>
</name><name>
<surname>Goto</surname>
<given-names>Y</given-names>
</name><name>
<surname>Kaneko</surname>
<given-names>N</given-names>
</name><name>
<surname>Sakamoto</surname>
<given-names>T</given-names>
</name><name>
<surname>Hashiguchi</surname>
<given-names>Y</given-names>
</name><name>
<surname>Moriyama</surname>
<given-names>M</given-names>
</name><name>
<surname>Toyoshima</surname>
<given-names>T</given-names>
</name><name>
<surname>Kitamura</surname>
<given-names>R</given-names>
</name><name>
<surname>Tanaka</surname>
<given-names>H</given-names>
</name><name>
<surname>Oobu</surname>
<given-names>K</given-names>
</name><name>
<surname>Kiyoshima</surname>
<given-names>T</given-names>
</name><name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018 Jul;47(7):836-845.</source>
<pub-id pub-id-type="pmid">29395669</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ijom.2018.01.004</pub-id>
</element-citation>
    </ref>
    <ref id="B8"><label>8</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Montler</surname>
<given-names>R</given-names>
</name><name>
<surname>Bell</surname>
<given-names>RB</given-names>
</name><name>
<surname>Thalhofer</surname>
<given-names>C</given-names>
</name><name>
<surname>Leidner</surname>
<given-names>R</given-names>
</name><name>
<surname>Feng</surname>
<given-names>Z</given-names>
</name><name>
<surname>Fox</surname>
<given-names>BA</given-names>
</name><name>
<surname>Cheng</surname>
<given-names>AC</given-names>
</name><name>
<surname>Bui</surname>
<given-names>TG</given-names>
</name><name>
<surname>Tucker</surname>
<given-names>C</given-names>
</name><name>
<surname>Hoen</surname>
<given-names>H</given-names>
</name><name>
<surname>Weinberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunology. 2016 Apr 15;5(4):e70.</source>
<pub-id pub-id-type="pmid">27195113</pub-id>
<pub-id pub-id-type="pmcid">PMC 4855266</pub-id>
<pub-id pub-id-type="doi">10.1038/cti.2016.16</pub-id>
</element-citation>
    </ref>
    <ref id="B9"><label>9</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Feldman</surname>
<given-names>AT</given-names>
</name><name>
<surname>Wolfe</surname>
<given-names>D</given-names>
</name>
</person-group>
<source>
Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 2014;1180:31-43.</source>
<pub-id pub-id-type="pmid">25015141</pub-id>
<pub-id pub-id-type="doi">10.1007/978-1-4939-1050-2_3</pub-id>
</element-citation>
    </ref>
    <ref id="B10"><label>10</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Slootweg</surname>
<given-names>PJ</given-names>
</name><name>
<surname>El-Naggar</surname>
<given-names>AK</given-names>
</name>
</person-group>
<source>
World Health Organization 4th edition of head and neck tumor classification: insight into the consequential modifications. Virchows Arch. 2018 Mar;472(3):311-313.</source>
<pub-id pub-id-type="pmid">29450648</pub-id>
<pub-id pub-id-type="doi">10.1007/s00428-018-2320-6</pub-id>
</element-citation>
    </ref>
    <ref id="B11"><label>11</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Akhter</surname>
<given-names>M</given-names>
</name><name>
<surname>Hossain</surname>
<given-names>S</given-names>
</name><name>
<surname>Rahman</surname>
<given-names>QB</given-names>
</name><name>
<surname>Molla</surname>
<given-names>MR</given-names>
</name>
</person-group>
<source>
A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. J Oral Maxillofac Pathol. 2011 May;15(2):168-76.</source>
<pub-id pub-id-type="pmid">22529575</pub-id>
<pub-id pub-id-type="pmcid">PMC 3329698</pub-id>
<pub-id pub-id-type="doi">10.4103/0973-029X.84485</pub-id>
</element-citation>
    </ref>
    <ref id="B12"><label>12</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Santos Lima</surname>
<given-names>EC</given-names>
</name><name>
<surname>Minoprio</surname>
<given-names>P</given-names>
</name>
</person-group>
<source>
Chagas' disease is attenuated in mice lacking gamma delta T cells. Infect Immun. 1996 Jan;64(1):215-21.</source>
<pub-id pub-id-type="pmid">8557342</pub-id>
<pub-id pub-id-type="pmcid">PMC 173748</pub-id>
<pub-id pub-id-type="doi">10.1128/iai.64.1.215-221.1996</pub-id>
</element-citation>
    </ref>
    <ref id="B13"><label>13</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Souza</surname>
<given-names>VG</given-names>
</name><name>
<surname>Santos</surname>
<given-names>DJS</given-names>
</name><name>
<surname>Silva</surname>
<given-names>AG</given-names>
</name><name>
<surname>Ribeiro</surname>
<given-names>RIMA</given-names>
</name><name>
<surname>Loyola</surname>
<given-names>AM</given-names>
</name><name>
<surname>Cardoso</surname>
<given-names>SV</given-names>
</name><name>
<surname>Miranda</surname>
<given-names>CSS</given-names>
</name><name>
<surname>Cardoso</surname>
<given-names>LPV</given-names>
</name>
</person-group>
<source>
Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma. J Appl Oral Sci. 2022 Feb 21;30:e20210344.</source>
<pub-id pub-id-type="pmid">35195152</pub-id>
<pub-id pub-id-type="pmcid">PMC 8860405</pub-id>
<pub-id pub-id-type="doi">10.1590/1678-7757-2021-0344</pub-id>
</element-citation>
    </ref>
    <ref id="B14"><label>14</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Cohen</surname>
<given-names>EEW</given-names>
</name><name>
<surname>Bell</surname>
<given-names>RB</given-names>
</name><name>
<surname>Bifulco</surname>
<given-names>CB</given-names>
</name><name>
<surname>Burtness</surname>
<given-names>B</given-names>
</name><name>
<surname>Gillison</surname>
<given-names>ML</given-names>
</name><name>
<surname>Harrington</surname>
<given-names>KJ</given-names>
</name><name>
<surname>Le</surname>
<given-names>QT</given-names>
</name><name>
<surname>Lee</surname>
<given-names>NY</given-names>
</name><name>
<surname>Leidner</surname>
<given-names>R</given-names>
</name><name>
<surname>Lewis</surname>
<given-names>RL</given-names>
</name><name>
<surname>Licitra</surname>
<given-names>L</given-names>
</name><name>
<surname>Mehanna</surname>
<given-names>H</given-names>
</name><name>
<surname>Mell</surname>
<given-names>LK</given-names>
</name><name>
<surname>Raben</surname>
<given-names>A</given-names>
</name><name>
<surname>Sikora</surname>
<given-names>AG</given-names>
</name><name>
<surname>Uppaluri</surname>
<given-names>R</given-names>
</name><name>
<surname>Whitworth</surname>
<given-names>F</given-names>
</name><name>
<surname>Zandberg</surname>
<given-names>DP</given-names>
</name><name>
<surname>Ferris</surname>
<given-names>RL</given-names>
</name>
</person-group>
<source>
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 Jul 15;7(1):184.</source>
<pub-id pub-id-type="pmid">31307547</pub-id>
<pub-id pub-id-type="pmcid">PMC 6632213</pub-id>
<pub-id pub-id-type="doi">10.1186/s40425-019-0662-5</pub-id>
</element-citation>
    </ref>
    <ref id="B15"><label>15</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Mukaka</surname>
<given-names>MM</given-names>
</name>
</person-group>
<source>
Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012 Sep;24(3):69-71.</source>
<pub-id pub-id-type="pmid">23638278</pub-id>
<pub-id pub-id-type="pmcid">PMC 3576830</pub-id>
</element-citation>
    </ref>
    <ref id="B16"><label>16</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Ram</surname>
<given-names>H</given-names>
</name><name>
<surname>Sarkar</surname>
<given-names>J</given-names>
</name><name>
<surname>Kumar</surname>
<given-names>H</given-names>
</name><name>
<surname>Konwar</surname>
<given-names>R</given-names>
</name><name>
<surname>Bhatt</surname>
<given-names>ML</given-names>
</name><name>
<surname>Mohammad</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>
Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg. 2011 Jun;10(2):132-7.</source>
<pub-id pub-id-type="pmid">22654364</pub-id>
<pub-id pub-id-type="pmcid">PMC 3177522</pub-id>
<pub-id pub-id-type="doi">10.1007/s12663-011-0195-z</pub-id>
</element-citation>
    </ref>
    <ref id="B17"><label>17</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Rivera</surname>
<given-names>C</given-names>
</name>
</person-group>
<source>
Essentials of oral cancer. Int J Clin Exp Pathol. 2015 Sep 1;8(9):11884-94.</source>
<pub-id pub-id-type="pmid">26617944</pub-id>
<pub-id pub-id-type="pmcid">PMC 3576830</pub-id>
</element-citation>
    </ref>
    <ref id="B18"><label>18</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Goertzen</surname>
<given-names>C</given-names>
</name><name>
<surname>Mahdi</surname>
<given-names>H</given-names>
</name><name>
<surname>Laliberte</surname>
<given-names>C</given-names>
</name><name>
<surname>Meirson</surname>
<given-names>T</given-names>
</name><name>
<surname>Eymael</surname>
<given-names>D</given-names>
</name><name>
<surname>Gil-Henn</surname>
<given-names>H</given-names>
</name><name>
<surname>Magalhaes</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>
Oral inflammation promotes oral squamous cell carcinoma invasion. Oncotarget. 2018 Jun 26;9(49):29047-29063.</source>
<pub-id pub-id-type="pmid">30018735</pub-id>
<pub-id pub-id-type="pmcid">PMC 6044370</pub-id>
<pub-id pub-id-type="doi">10.18632/oncotarget.25540</pub-id>
</element-citation>
    </ref>
    <ref id="B19"><label>19</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Kujan</surname>
<given-names>O</given-names>
</name><name>
<surname>Oliver</surname>
<given-names>RJ</given-names>
</name><name>
<surname>Khattab</surname>
<given-names>A</given-names>
</name><name>
<surname>Roberts</surname>
<given-names>SA</given-names>
</name><name>
<surname>Thakker</surname>
<given-names>N</given-names>
</name><name>
<surname>Sloan</surname>
<given-names>P</given-names>
</name>
</person-group>
<source>
Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol. 2006 Nov;42(10):987-93.</source>
<pub-id pub-id-type="pmid">16731030</pub-id>
<pub-id pub-id-type="doi">10.1016/j.oraloncology.2005.12.014</pub-id>
</element-citation>
    </ref>
    <ref id="B20"><label>20</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Meeusen</surname>
<given-names>E</given-names>
</name><name>
<surname>Lim</surname>
<given-names>E</given-names>
</name><name>
<surname>Mathivanan</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>
Secreted Tumor Antigens - Immune Biomarkers for Diagnosis and Therapy. Proteomics. 2017 Dec;17(23-24).</source>
<pub-id pub-id-type="pmid">28714192</pub-id>
<pub-id pub-id-type="doi">10.1002/pmic.201600442</pub-id>
</element-citation>
    </ref>
    <ref id="B21"><label>21</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Dave</surname>
<given-names>K</given-names>
</name><name>
<surname>Ali</surname>
<given-names>A</given-names>
</name><name>
<surname>Magalhaes</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>
Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep. 2020 Jun 16;10(1):9705.</source>
<pub-id pub-id-type="pmid">32546692</pub-id>
<pub-id pub-id-type="pmcid">PMC 7297711</pub-id>
<pub-id pub-id-type="doi">10.1038/s41598-020-66257-6</pub-id>
</element-citation>
    </ref>
    <ref id="B22"><label>22</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Shah</surname>
<given-names>S</given-names>
</name><name>
<surname>Caruso</surname>
<given-names>A</given-names>
</name><name>
<surname>Cash</surname>
<given-names>H</given-names>
</name><name>
<surname>Waes</surname>
<given-names>CV</given-names>
</name><name>
<surname>Allen</surname>
<given-names>CT</given-names>
</name>
</person-group>
<source>
Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. Head Neck. 2016 Aug;38(8):1176-86.</source>
<pub-id pub-id-type="pmid">27061215</pub-id>
<pub-id pub-id-type="pmcid">PMC 6669909</pub-id>
<pub-id pub-id-type="doi">10.1002/hed.24269</pub-id>
</element-citation>
    </ref>
    <ref id="B23"><label>23</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Wuerdemann</surname>
<given-names>N</given-names>
</name><name>
<surname>Gültekin</surname>
<given-names>SE</given-names>
</name><name>
<surname>Pütz</surname>
<given-names>K</given-names>
</name><name>
<surname>Wittekindt</surname>
<given-names>C</given-names>
</name><name>
<surname>Huebbers</surname>
<given-names>CU</given-names>
</name><name>
<surname>Sharma</surname>
<given-names>SJ</given-names>
</name><name>
<surname>Eckel</surname>
<given-names>H</given-names>
</name><name>
<surname>Schubotz</surname>
<given-names>AB</given-names>
</name><name>
<surname>Gattenlöhner</surname>
<given-names>S</given-names>
</name><name>
<surname>Büttner</surname>
<given-names>R</given-names>
</name><name>
<surname>Speel</surname>
<given-names>EJ</given-names>
</name><name>
<surname>Klussmann</surname>
<given-names>JP</given-names>
</name><name>
<surname>Wagner</surname>
<given-names>S</given-names>
</name><name>
<surname>Quaas</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>
PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. Int J Mol Sci. 2020 Jul 23;21(15):5228.</source>
<pub-id pub-id-type="pmid">32718057</pub-id>
<pub-id pub-id-type="pmcid">PMC 7432501</pub-id>
<pub-id pub-id-type="doi">10.3390/ijms21155228</pub-id>
</element-citation>
    </ref>
    <ref id="B24"><label>24</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Bussu</surname>
<given-names>F</given-names>
</name><name>
<surname>Graziani</surname>
<given-names>C</given-names>
</name><name>
<surname>Gallus</surname>
<given-names>R</given-names>
</name><name>
<surname>Cittadini</surname>
<given-names>A</given-names>
</name><name>
<surname>Galli</surname>
<given-names>J</given-names>
</name><name>
<surname>DE Corso</surname>
<given-names>E</given-names>
</name><name>
<surname>DI Cintio</surname>
<given-names>G</given-names>
</name><name>
<surname>Corbi</surname>
<given-names>M</given-names>
</name><name>
<surname>Almadori</surname>
<given-names>G</given-names>
</name><name>
<surname>Boninsegna</surname>
<given-names>A</given-names>
</name><name>
<surname>Paludetti</surname>
<given-names>G</given-names>
</name><name>
<surname>Sgambato</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>
IFN-γ and other serum cytokines in head and neck squamous cell carcinomas. Acta Otorhinolaryngol Ital. 2018 Apr;38(2):94-102.</source>
<pub-id pub-id-type="pmid">29967556</pub-id>
<pub-id pub-id-type="pmcid">PMC 6028810</pub-id>
<pub-id pub-id-type="doi">10.14639/0392-100X-1530</pub-id>
</element-citation>
    </ref>
    <ref id="B25"><label>25</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Conti-Freitas</surname>
<given-names>LC</given-names>
</name><name>
<surname>Foss-Freitas</surname>
<given-names>MC</given-names>
</name><name>
<surname>Mamede</surname>
<given-names>RC</given-names>
</name><name>
<surname>Foss</surname>
<given-names>NT</given-names>
</name>
</person-group>
<source>
Interferon-gamma and interleukin-10 production by mononuclear cells from patients with advanced head and neck cancer. Clinics (Sao Paulo). 2012;67(6):587-90.</source>
<pub-id pub-id-type="pmid">22760896</pub-id>
<pub-id pub-id-type="doi">10.6061/clinics/2012(06)07</pub-id>
</element-citation>
    </ref>
    <ref id="B26"><label>26</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>van Eeden</surname>
<given-names>WA</given-names>
</name><name>
<surname>van Hemert</surname>
<given-names>AM</given-names>
</name><name>
<surname>Carlier</surname>
<given-names>IVE</given-names>
</name><name>
<surname>Penninx</surname>
<given-names>BWJH</given-names>
</name><name>
<surname>Lamers</surname>
<given-names>F</given-names>
</name><name>
<surname>Fried</surname>
<given-names>EI</given-names>
</name><name>
<surname>Schoevers</surname>
<given-names>R</given-names>
</name><name>
<surname>Giltay</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<source>
Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression. Transl Psychiatry. 2020 Jul 15;10(1):235.</source>
<pub-id pub-id-type="pmid">32669537</pub-id>
<pub-id pub-id-type="pmcid">PMC 7363825</pub-id>
<pub-id pub-id-type="doi">10.1038/s41398-020-00920-4</pub-id>
</element-citation>
    </ref>
    </ref-list>
</back>
</article>